isosakuranetin has been researched along with luteolin in 4 studies
Studies (isosakuranetin) | Trials (isosakuranetin) | Recent Studies (post-2010) (isosakuranetin) | Studies (luteolin) | Trials (luteolin) | Recent Studies (post-2010) (luteolin) |
---|---|---|---|---|---|
28 | 0 | 20 | 2,402 | 15 | 1,648 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (50.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Augereau, JM; Billon, M; Gleye, J; Herbert, JM; Lale, A; Leconte, M | 1 |
Habtemariam, S | 1 |
Itoh, T; Sakakibara, H; Shimoi, K; Takemura, H; Yamamoto, K | 1 |
Batista-Gonzalez, A; Brunhofer, G; Fallarero, A; Gopi Mohan, C; Karlsson, D; Shinde, P; Vuorela, P | 1 |
4 other study(ies) available for isosakuranetin and luteolin
Article | Year |
---|---|
Ability of different flavonoids to inhibit the procoagulant activity of adherent human monocytes.
Topics: Amino Acid Sequence; Blood Coagulation; Cell Adhesion; Endotoxins; Flavonoids; Humans; In Vitro Techniques; Interleukin-1; Molecular Sequence Data; Monocytes | 1996 |
Flavonoids as inhibitors or enhancers of the cytotoxicity of tumor necrosis factor-alpha in L-929 tumor cells.
Topics: Animals; Apoptosis; Drug Synergism; Flavonoids; Mice; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 1997 |
Selective inhibition of methoxyflavonoids on human CYP1B1 activity.
Topics: Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP1A1; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1B1; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Flavonoids; Humans; Models, Molecular; Structure-Activity Relationship | 2010 |
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
Topics: Acetylcholinesterase; Amyloid beta-Peptides; Benzophenanthridines; Binding Sites; Butyrylcholinesterase; Catalytic Domain; Cholinesterase Inhibitors; Humans; Isoquinolines; Kinetics; Molecular Docking Simulation; Structure-Activity Relationship | 2012 |